Advances in the treatment of melanoma have focused on overcoming tumor-induced immune suppression and were initially established in the adjuvant setting with the use of IFN-α and HDB IL-2 in the treatment of metastatic disease. This evidence concerns the gene IFNA1 and neoplasm.